Patents by Inventor Michael Weiss
Michael Weiss has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20220002373Abstract: A single-chain insulin analogue containing an engineered C-domain segment of lengths 4-11 conforming to the sequence pattern [Asp/Glu]-Ala-An-Ala-Xaa where An designates a sub-segment of 0-7 Alanine residues and where Xaa designates an amino-acid residue selected from the amino acids Alanine, Arginine, Asparagine, Aspartic Acid, Glutamic Acid, Histine, Lysine and Serine. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include standard or non-standard modifications that (i) augment the stability of insulin, (ii) cause a shift in the isoelectric point to enhance or impair the solubilty of the protein at neutral pH or (iii) reduce cross-binding of the protein to the Type I IGF receptor. A method of treating a patient with diabetes mellitus comprising the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient.Type: ApplicationFiled: November 19, 2019Publication date: January 6, 2022Inventor: Michael A. WEISS
-
Patent number: 11208453Abstract: A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at positon A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.Type: GrantFiled: November 21, 2017Date of Patent: December 28, 2021Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Publication number: 20210386831Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.Type: ApplicationFiled: June 1, 2021Publication date: December 16, 2021Inventors: Jeffrey I. JOSEPH, Richard William BERENSON, Bruce FRANK, Michael A. WEISS, Thomas HATTIER, Gregory DUBÉ, Zhiqiang CHEN
-
Publication number: 20210371489Abstract: A single-chain insulin analogues may comprise an insulin B-chain polypeptide sequence connected by a connecting polypeptide (or C-domain) sequence to an insulin A-chain polypeptide sequence. The connecting polypeptide sequence may be Glu-Xaa-Gly-Pro-Arg-Arg where Xaa is Glu or Ala. The insulin analogues may additionally comprise Glu or His substitutions at the position corresponding to A8 of human insulin and/or a Glu substitution at the position corresponding to A14 of human insulin. In some embodiments, the insulin analogues may additionally comprise either a Pro or Glu at the positions corresponding to B28 and B29 of wild-type insulin. Additional substitutions may comprise Phe or Trp at the position corresponding to A13 of wild type insulin and/or Gln, Arg, Phe, or Glu at the position corresponding to A17 of wild type insulin. In some embodiments, a Glu substitution at the position corresponding to B16 of wild type insulin may be present.Type: ApplicationFiled: September 23, 2019Publication date: December 2, 2021Inventor: Michael A. WEISS
-
Patent number: 11174303Abstract: A single-chain insulin analogue comprises a B-chain insulin polypeptide connected to an A-chain insulin polypeptide by a C-domain polypeptide. The B-chain insulin polypeptide contains a Cysteine substitution at position B4. The A-chain insulin polypeptide contains a Cysteine substitution at position A10. The C-domain polypeptide is 4 to 11 amino acids long. The analogue mitigates the unfavorable activity of this 4th disulfide bridge in conventional two-chain insulin analogues resulting in a duration of insulin signaling similar to that of wild-type insulin. A method of treating a patient with diabetes mellitus comprises the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient. Use of a single-chain insulin analogue of the present invention in an insulin delivery device (such as a pump or pen) or as part of a high-temperature polymer-melt manufacturing process.Type: GrantFiled: March 7, 2018Date of Patent: November 16, 2021Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Patent number: 11142560Abstract: A single-chain insulin comprises a C-domain of 6 to 11 amino acid residues comprising at least two acidic residues at the N-terminal side of the C-domain and at least two basic residues at the C-terminal side of the C-domain peptide, a basic amino acid residue at the position corresponding to A8 of human insulin, and an acidic amino acid residue at the position corresponding to A14 of human insulin. The C-domain may contain a 2 to 4 amino acid joint region between the acidic and basic residues. Residues C1 and C2 may have a net negative charge of ?1 or ?2; and the remaining C-domain segment may culminates with two basic residues. A pharmaceutical composition comprises the single-chain insulin, formulated at a pH within the range 7.0 to 8.0, and may be formulated at a concentration of 0.6 mM to 5.0 mM and/or at a strength of U-100 to U-1000.Type: GrantFiled: August 26, 2019Date of Patent: October 12, 2021Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Patent number: 11131516Abstract: The present invention generally relates to a firearm shell casing receiver. The invention generally comprises of a horseshoe shaped member with widened ends and an arm member that serves as a clip to allow for the attachment of a receiver vesicle. To utilize the current invention, the shell casing receiver securely grips onto a firearm's platform whereas the clip portion holds a receiver vesicle to capture any spent ammunition.Type: GrantFiled: January 21, 2020Date of Patent: September 28, 2021Inventors: Chong Lam, Michael Weiss
-
Patent number: 11112380Abstract: A sensor arrangement for determining at least one measurand of a measuring medium includes at least one first sensor with a first sensing element used to record measured values of a first measurand of the measuring medium, a housing having a housing wall which surrounds a housing interior containing the first sensing element, wherein the housing interior contains a medium in particular, a liquid which has a predetermined value of the first measurand.Type: GrantFiled: September 6, 2019Date of Patent: September 7, 2021Assignee: Endress+Hauser Conducta GmbH+Co. KGInventors: Michael Weiss, Angela Eubisch, Michael Hanko
-
Patent number: 11052502Abstract: A power-tool cooling apparatus for a portable power tool includes a first fan configured to generate a first cooling fluid flow to cool a drive unit of the portable power tool, and a second fan that generates a further cooling fluid flow to cool an electronics unit of the portable power-tool. A third fan generates a third cooling fluid flow to cool a second electronics unit of the power-tool, and supplies cooling fluid to the first cooling fluid flow.Type: GrantFiled: December 7, 2018Date of Patent: July 6, 2021Assignee: Robert Bosch GmbHInventors: Michael Weiss, Torsten Riek, Andreas Schlegel, Steffen Tiede, Christian Lang, Hardy Schmid, Juergen Dietel, Benjamin Fischle
-
Publication number: 20210162014Abstract: An insulin composition comprises an insulin analogue and polymer blend. The insulin analogue contains cysteine substitutions at positions B4 and A10 (to form cystine B4-A10), and one or more additional substitutions selected from the group consisting of: a connecting domain of 5-11 amino acids between insulin A- and B domains; a non-beta-branched amino-acid substitution at position A8; a non-beta-branched acidic or polar side chain at position A14; a halogenic modification of PheB24 at the ortho position; and substitution of lysine at position B29 by Glu, Ala, Val, Ile, Leu, amino-propionic acid, amino-butryic acid, or Norleucine. The insulin analogue is compatible with a process of manufacture that includes one or more steps within the temperature range 90-120 oC. The encapsulated insulin analogue may optionally contain free PEG or be PEGylated. The insulin analogue-encapsulated polymer blend may be cast as a microneedle patch for topical administration or as micropellets for subcutaneous injection.Type: ApplicationFiled: December 23, 2016Publication date: June 3, 2021Inventors: Michael WEISS, Jon POKORSKI
-
Patent number: 10995129Abstract: An insulin analogue comprises an insulin A-chain polypeptide and an insulin B-chain polypeptide. The A-chain polypeptide contains a Glu substitution at a position corresponding to position A8, and an Ala, Glu, Gln, His, Tyr, Phe or Trp substitution at a position A13, relative to wild type insulin. The B-chain polypeptide contains a cyclohexanylalanine substitution at position B24, relative to wild type insulin. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.Type: GrantFiled: July 26, 2019Date of Patent: May 4, 2021Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Patent number: 10865888Abstract: A connection fitting (8) of a heat management module (1) of an internal combustion engine can be inserted into a receptacle hole (9) in a housing (2) of the heat management module. The aim is to be able to bias a sealing ring (16) of the nozzle against a rotary valve (3) using a compression spring element (13). The connection fitting is to be provided with a stop (24) that limits the longitudinal movement of the sealing ring in the direction of the rotary valve.Type: GrantFiled: February 3, 2017Date of Patent: December 15, 2020Assignee: SCHAEFFLER TECHNOLOGIES AG & CO. KGInventors: Uli Grosskopf, Michael Weiss
-
Patent number: 10822386Abstract: A polypeptide comprises an insulin B-chain sequence having the substitutions: Asp at position B10, Ala at position B12, and Glu at position B29, relative to wild type insulin. The polypeptide may additionally comprise a substitution of a halogenated phenylalanine at position B24, such as ortho-fluoro-phenylalanine. Optionally, the polypeptide may additionally comprise a C-terminal dipeptide extension wherein at least one amino acid in the dipeptide contains an acidic side chain, such as Glu-Glu, and/or an N-terminal deletion of one, two or three residues from the B chain. An insulin analogue may comprise any of these polypeptides with an insulin A-chain polypeptide that optionally contains a Glu A8 substitution. The A-chain sequence may be a separate polypeptide or it may be joined to the B-chain polypeptide by a two amino acid linker. The linker may be Trp-Lys or Ala-Lys. The insulin analogue may be used to treat a patient with diabetes mellitus.Type: GrantFiled: December 24, 2015Date of Patent: November 3, 2020Assignee: Case Western Reserve UniversityInventor: Michael Weiss
-
Patent number: 10745458Abstract: An insulin analogue comprises a B-chain polypeptide containing a cyclohexanylalanine substitution at position B24 and optionally containing additional amino-acid substitutions at positions A8, B28, and/or B29. A proinsulin analogue or single-chain insulin analogue contains a B domain containing a cyclohexanylalanine substitution at position B24 and optionally contains additional amino-acid substitutions at positions A8, B28, and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin. A nucleic acid encoding such an insulin analogue is also provided. A method of lowering the blood sugar of a patient comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient. A method of semi-synthesis using an unprotected octapeptide by means of modification of an endogenous tryptic site by non-standard amino-acid substitutions.Type: GrantFiled: November 22, 2018Date of Patent: August 18, 2020Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Publication number: 20200232736Abstract: The present invention generally relates to a firearm shell casing receiver. The invention generally comprises of a horseshoe shaped member with widened ends and an arm member that serves as a clip to allow for the attachment of a receiver vesicle. To utilize the current invention, the shell casing receiver securely grips onto a firearm's platform whereas the clip portion holds a receiver vesicle to capture any spent ammunition.Type: ApplicationFiled: January 21, 2020Publication date: July 23, 2020Inventors: Chong Lam, Michael Weiss
-
Patent number: 10703792Abstract: A two-chain insulin analogue contains Aspartic Acid at position B10 and penta-fluoro-Phenylalanine at position B24, optionally Histidine or Glutamic Acid at position A8, optionally additional substitutions or modifications at positions A13 and/or A14 and/or B28 and/or B29. The analogue may be an analogue of a mammalian insulin, such as human insulin, may optionally include (i) N-terminal deletion of one, two or three residues from the B chain, (ii) a mono-peptide or dipeptide C-terminal extension of the B-chain containing at least one acidic residue, and (iii) other modifications known in the art to enhance the stability of insulin. Formulations of the above analogues at successive strengths U-100 to U-1000 in soluble solutions at at least pH value in the range 7.0-8.0 in the absence or presence of zinc ions at a molar ratio of 0.00-0.10 zinc ions per insulin analogue monomer.Type: GrantFiled: July 25, 2019Date of Patent: July 7, 2020Assignee: Case Western Reserve UniversityInventor: Michael A. Weiss
-
Publication number: 20200138911Abstract: The present invention provides rapid-acting insulin and insulin analogue formulations. The invention further provides delivery devices, particularly infusion sets, which allow for the rapid absorption of insulin and insulin analogues, as well as other active agents. Methods of using the insulin and insulin analogue formulations as well as the insulin delivery devices for treating subjects with diabetes mellitus are also provided.Type: ApplicationFiled: January 2, 2020Publication date: May 7, 2020Inventors: Jeffrey I. JOSEPH, Richard William BERENSON, Bruce FRANK, Michael A. WEISS, Thomas HATTIER, Gregory DUBÉ, Zhiqiang CHEN
-
Publication number: 20200140516Abstract: A polypeptide comprises an insulin B-chain sequence having the substitutions: Asp at position B10, Ala at position B12, and Glu at position B29, relative to wild type insulin. The polypeptide may additionally comprise a substitution of a halogenated phenylalanine at position B24, such as ortho-fluoro-phenylalanine. Optionally, the polypeptide may additionally comprise a C-terminal dipeptide extension wherein at least one amino acid in the dipeptide contains an acidic side chain, such as Glu-Glu, and/or an N-terminal deletion of one, two or three residues from the B chain. An insulin analogue may comprise any of these polypeptides with an insulin A-chain polypeptide that optionally contains a Glu A8 substitution. The A-chain sequence may be a separate polypeptide or it may be joined to the B-chain polypeptide by a two amino acid linker. The linker may be Trp-Lys or Ala-Lys. The insulin analogue may be used to treat a patient with diabetes mellitus.Type: ApplicationFiled: December 24, 2015Publication date: May 7, 2020Applicant: Case Western Reserve UniversityInventor: Michael WEISS
-
Publication number: 20200140517Abstract: A single-chain insulin analogue comprises a B-chain insulin polypeptide connected to an A-chain insulin polypeptide by a C-domain polypeptide. The B-chain insulin polypeptide contains a Cysteine substitution at position B4. The A-chain insulin polypeptide contains a Cysteine substitution at position A10. The C-domain polypeptide is 4 to 11 amino acids long. The analogue mitigates the unfavorable activity of this 4th disulfide bridge in conventional two-chain insulin analogues resulting in a duration of insulin signaling similar to that of wild-type insulin. A method of treating a patient with diabetes mellitus comprises the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient. Use of a single-chain insulin analogue of the present invention in an insulin delivery device (such as a pump or pen) or as part of a high-temperature polymer-melt manufacturing process.Type: ApplicationFiled: March 7, 2018Publication date: May 7, 2020Inventor: Michael A. WEISS
-
Publication number: 20200130864Abstract: A method and system provide the ability to autonomously operate an unmanned aerial system (UAS) over long durations of time. The UAS vehicle autonomously takes off from a take-off landing-charging station and autonomously executes a mission. The mission includes data acquisition instructions in a defined observation area. Upon mission completion, the UAS autonomously travels to a target landing-charging station and performs an autonomous precision landing on the target landing-charging station. The UAS autonomously re-charges via the target landing-charging station. Once re-charged, the UAS is ready to execute a next sortie. When landed, the UAS autonomously transmits mission data to the landing-charging station for in situ or cloud-based data processing.Type: ApplicationFiled: October 29, 2019Publication date: April 30, 2020Applicant: California Institute of TechnologyInventors: Roland Brockers, Stephan Michael Weiss, Danylo Malyuta, Christian Brommer, Daniel Robert Hentzen